Goblet cell differentiation subgroups in colorectal cancer.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
22 Oct 2024
Historique:
medline: 14 10 2024
pubmed: 14 10 2024
entrez: 14 10 2024
Statut: ppublish

Résumé

The poor prognosis of relatively undifferentiated cancers has long been recognized, suggesting that selection against differentiation and in favor of uncontrolled growth is one of the most powerful drivers of cancer progression. Goblet cells provide the mucous surface of the gut, and when present in colorectal cancers (CRC), the cancers are called mucinous. We have used the presence of MUC2, the main mucous product of goblet cells, and an associated gene product, TFF3, to classify a large panel of nearly 80 CRC-derived cell lines into five categories based on their levels of MUC2 and TFF3 expression. We have then shown that these five patterns of expression can be easily identified in the direct analysis of tumor specimens allowing a much finer characterization of CRCs with respect to the presence of goblet cell differentiation. In particular, about 30% of all CRCs fall into the category of expressing TFF3 but not MUC2, which has not previously been acknowledged. Using the cell line data, we suggest that there are up to 12 genes (

Identifiants

pubmed: 39401352
doi: 10.1073/pnas.2414213121
doi:

Substances chimiques

Trefoil Factor-3 0
Mucin-2 0
TFF3 protein, human 0
MUC2 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2414213121

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Gulnar Abdullayeva (G)

Department of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom.
Institute of Molecular Biology and Biotechnologies, Ministry of Science and Education of the Republic of Azerbaijan, Baku AZ1073, Azerbaijan.
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, OX3 7TY, United Kingdom.

Haoyu Liu (H)

Tencent Technology (Shenzhen) Co. Ltd., Shenzhen City 518000, China.

Ta-Chun Liu (TC)

Hayawaka Building, Oxford OX4 4GA, United Kingdom.

Alison Simmons (A)

Medical Research Council (MRC) Translational Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DS, United Kingdom.
Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, United Kingdom.

Marco Novelli (M)

University College London Department of Pathology, London WC1E 6HX, United Kingdom.

Irada Huseynova (I)

Institute of Molecular Biology and Biotechnologies, Ministry of Science and Education of the Republic of Azerbaijan, Baku AZ1073, Azerbaijan.

Viorica L Lastun (VL)

Department of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom.

Walter Bodmer (W)

Department of Oncology, University of Oxford, Oxford OX3 7DQ, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH